Journal of Heart and Lung Transplantation

Article	Citations
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation	377
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report — 2021; Focus on recipient charact	273
A 5-year single-center early experience of heart transplantation from donation after circulatory-determined death donors	176
The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients	159
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report — 2021; Focus on recipient charac	159
Early US experience with cardiac donation after circulatory death (DCD) using normothermic regional perfusion	130
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry	129
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response	113
Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients	106
MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry	83
Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience	79
The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update	69
Mortality in patients with cardiogenic shock supported with VA ECMO: A systematic review and meta-analysis evaluating the impact of etiology on 29,289 patients	60
Heart transplantation following donation after circulatory death: Expanding the donor pool	58
SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients	54
Berlin Heart EXCOR and ACTION post-approval surveillance study report	53
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report—2022; focus on lung transplant reci	52
International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation	51
The impact of frailty on mortality after heart transplantation	51
ISHLT consensus statement for the selection and management of pediatric and congenital heart disease patients on ventricular assist devices Endorsed by the American Heart Association	47
Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT	47
COVID-19 vaccination in our transplant recipients: The time is now	47
Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study	47
Donor heart selection: Evidence-based guidelines for providers	46
Systemic ventricular assist device support in Fontan patients: A report by ACTION	43

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric heart transplantation report — 2021; focus on recipient ch	41
Increased early acute cellular rejection events in hepatitis C-positive heart transplantation	41
Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension	40
Improved survival after heart transplantation in patients bridged with extracorporeal membrane oxygenation in the new allocation system	40
Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment	39
Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes	38
First in man evaluation of a novel circulatory support device: Early experience with the Impella 5.5 after CE mark approval in Germany	37
Clinical myocardial recovery in advanced heart failure with long term left ventricular assist device support	37
Mitochondrial transplantation for myocardial protection in ex-situ‒perfused hearts donated after circulatory death	37
The International thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-ninth adult heart transplantation report—2022; focus on transplant for rest	36
Cell death and ischemia-reperfusion injury in lung transplantation	36
Right ventricular function and cardiopulmonary performance among patients with heart failure supported by durable mechanical circulatory support devices	36
Pregnancy in pulmonary arterial hypertension: Midterm outcomes of mothers and offspring	36
The results of a single-center experience with HeartMate 3 in a biventricular configuration	36
Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis	35
The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support	35
Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD)	33
Expanding Heart Transplants from Donors After Circulatory Death (DCD) - Results of the First Randomized Controlled Trial Using the Organ Care System (OCS™) Heart - (OCS DCD Heart Trial)	33
Outcomes in the 2018 UNOS donor heart allocation system: A perspective on disparate analyses	33
Cell-free DNA beyond a biomarker for rejection: Biological trigger of tissue injury and potential therapeutics	32
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension	31
Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis	31
Less invasive surgical implant strategy and right heart failure after LVAD implantation	30
Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices – The CLEAR-LVAD study	30
Prediction of donor related lung injury in clinical lung transplantation using a validated ex vivo lung perfusion inflammation score	30
Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: A retrospective analysis	29
Comparison of combined heart‒liver vs heart-only transplantation in pediatric and young adult Fontan recipients	29
Ex situ heart perfusion: The past, the present, and the future	29
Long-term survival on LVAD support: Device complications and end-organ dysfunction limit long-term success	29
Gender and racial disparities in lung transplantation in the United States	28
Arterial oxygen and carbon dioxide tension and acute brain injury in extracorporeal cardiopulmonary resuscitation patients: Analysis of the extracorporeal life support organization registry	27
COVID-19 vaccination immune paresis in heart and lung transplantation	27
Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort	27
Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes	26
Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care	26
Bridging the survival gap in cystic fibrosis: An investigation of lung transplant outcomes in Canada and the United States	26
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric lung transplantation report — 2021; Focus on recipient cha	25
Percutaneous versus surgical cannulation for femoro-femoral VA-ECMO in patients with cardiogenic shock: Results from the Extracorporeal Life Support Organization Registry	25
Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment	25
A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation	25
Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension	25
Clinical utility of donor-derived cell-free DNA testing in cardiac transplantation	25
ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery	25
International consensus recommendations for anesthetic and intensive care management of lung transplantation. An EACTAIC, SCA, ISHLT, ESOT, ESTS, and AST approved document	25
Thoracoabdominal normothermic regional perfusion in donation after circulatory death does not restore brain blood flow	25
Transplanting thoracic COVID-19 positive donors: An institutional protocol and report of the first 14 cases	24
Risk factors for mortality in lung transplant recipients aged ≥65 years: A retrospective cohort study of 5,815 patients in the scientific registry of transplant recipients	24
Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction	24
Lung transplantation for idiopathic pulmonary fibrosis enriches for individuals with telomere-mediated disease	24
Pig heart and lung xenotransplantation: Present status	23

Contemporary trends in PGD incidence, outcomes, and therapies	23
The International thoracic organ transplant registry of the international society for heart and lung transplantation: Twenty-fifth pediatric heart transplantation report—2022; focus on infant heart tr	23
Reproductive health after thoracic transplantation: An ISHLT expert consensus statement	23
A novel method of donor‒recipient size matching in pediatric heart transplantation: A total cardiac volume‒predictive model	23
Recipient and surgical factors trigger severe primary graft dysfunction after heart transplant	22
CFTR modulator use in post lung transplant recipients	22
Therapeutic efficacy of large aligned cardiac tissue derived from induced pluripotent stem cell in a porcine ischemic cardiomyopathy model	22
Innate allorecognition in transplantation	21
Incidence and long-term outcome of heart transplantation patients who develop postoperative renal failure requiring dialysis	21
ISHLT position paper on thoracic organ transplantation in controlled donation after circulatory determination of death (cDCD)	21
Preservation by cold storage vs ex vivo normothermic perfusion of marginal donor hearts: clinical, histopathologic, and ultrastructural features	21
Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates	21
Aspiration of conjugated bile acids predicts adverse lung transplant outcomes and correlates with airway lipid and cytokine dysregulation	21
Complications of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: Impact on the outcome	21
Percutaneous RVAD with the Protek Duo for severe right ventricular primary graft dysfunction after heart transplant	21
Venous or arterial thromboses after venoarterial extracorporeal membrane oxygenation support: Frequency and risk factors	21
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study	21
The influence of mechanical Circulatory support on post-transplant outcomes in pediatric patients: A multicenter study from the International Society for Heart and Lung Transplantation (ISHLT) Registr	20
Risk factors of invasive fungal infections in lung transplant recipients: A systematic review and meta-analysis	20
Early United States experience with lung donation after circulatory death using thoracoabdominal normothermic regional perfusion	20
Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19	20
Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis	20
Azithromycin prophylaxis after lung transplantation is associated with improved overall survival	20
Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients	20
Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy	20
Remote ex vivo lung perfusion at a centralized evaluation facility	20
Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review	19
Improved clinical outcomes associated with the Impella 5.5 compared to the Impella 5.0 in contemporary cardiogenic shock and heart failure patients	19
The effect of COVID-19 on transplant function and development of CLAD in lung transplant patients: A multicenter experience	19
Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin	19
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence	19
The lung microbiome in lung transplantation	19
Molecular T-cell‒mediated rejection in transbronchial and mucosal lung transplant biopsies is associated with future risk of graft loss	19
A national pilot of donation after circulatory death (DCD) heart transplantation within the United Kingdom	19
MicroRNA-206 antagomiR‒enriched extracellular vesicles attenuate lung ischemia‒reperfusion injury through CXCL1 regulation in alveolar epithelial cells	18
Biology of myocardial recovery in advanced heart failure with long-term mechanical support	18
Exercise right ventricular ejection fraction predicts right ventricular contractile reserve	18
Lactate during ex-situ heart perfusion does not predict the requirement for mechanical circulatory support following donation after circulatory death (DCD) heart transplants	18
Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters	18
Use of metabolomics to identify strategies to improve and prolong ex vivo lung perfusion for lung transplants	18
ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, an	18
Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension	17
Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury	17
A CLUE for better assessment of donor lungs: Novel technique in clinical ex vivo lung perfusion	17
Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial	17
A simplified strategy for donor-recipient size-matching in lung transplant for interstitial lung disease	17
Surveillance for cardiac allograft vasculopathy: Practice variations among 50 pediatric heart transplant centers	17
Outcomes after heart transplantation and total artificial heart implantation: A multicenter study	17
A challenge to equity in transplantation: Increased center-level variation in short-term mechanical circulatory support use in the context of the updated U.S. heart transplant allocation policy	17
Pediatric heart transplantation following donation after circulatory death, distant procurement, and ex-situ perfusion	17
Indications and outcome after lung transplantation in children under 12 years of age: A 16-year single center experience	16
Right ventricular adaptation to pressure-overload: Differences between chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension	16
Successful salvage therapy for fungal bronchial anastomotic infection after –lung transplantation with an inhaled triazole anti-fungal PC945	16
Lung transplantation using allografts with more than 8 hours of ischemic time: A single-institution experience	16
Rotational thromboelastometry reduces blood loss and blood product usage after lung transplantation	16
Mitochondrial transplant after ischemia reperfusion promotes cellular salvage and improves lung function during ex-vivo lung perfusion	16
A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective	16
Resolution of post-lung transplant ischemia-reperfusion injury is modulated via Resolvin D1-FPR2 and Maresin 1-LGR6 signaling	16
Inflammatory responses in lungs from donation after brain death: Mechanisms and potential therapeutic targets	16
High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients	16
Donation after circulatory death heart procurement strategy impacts utilization and outcomes of concurrently procured abdominal organs	16
Initial bridge to transplant experience with a bioprosthetic autoregulated artificial heart	16
Graft survival in primary thoracic organ transplant recipients: A special report from the International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantati	15
Temporal shift and predictive performance of machine learning for heart transplant outcomes	15
Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort	15
Ventilation in the prone position improves oxygenation and results in more lungs being transplanted from organ donors with hypoxemia and atelectasis	15
Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients	15
Development of the Lung Transplant Frailty Scale (LT-FS)	15
Bronchiolitis obliterans syndrome is associated with increased senescent lymphocytes in the small airways	15
Heart transplantation outcomes in cardiac sarcoidosis	15
Effects of cold or warm ischemia and ex-vivo lung perfusion on the release of damage associated molecular patterns and inflammatory cytokines in experimental lung transplantation	15
Evaluation of 10°C as the optimal storage temperature for aspiration-injured donor lungs in a large animal transplant model	15
Impact of thoracotomy approach on right ventricular failure and length of stay in left ventricular assist device implants: an intermacs registry analysis	15
High-intensity interval training in patients with left ventricular assist devices: A pilot randomized controlled trial	15
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis	14
First Results of Soprano: Macitentan in Patients (pts) with Pulmonary Hypertension (PH) Post-Left Ventricular Assist Device (LVAD) Implantation	14
Stroke in pediatric ventricular assist device patients—a pedimacs registry analysis	14
Pulmonary artery pulsatility index as a predictor of right ventricular failure in left ventricular assist device recipients: A systematic review	14
Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE	14
Bridging to transplant with HeartMate 3 left ventricular assist devices in the new heart organ allocation system: An individualized approach	14

Innate immunity in lung transplantation	14
Lung transplant outcome following donation after euthanasia	14
Operating room extubation: A predictive factor for 1-year survival after double-lung transplantation	14
Temporary mechanical circulatory support: Devices, outcomes, and future directions	14
Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age	14
Idiopathic pulmonary arterial hypertension patients with a high H2FPEF-score: Insights from the Amsterdam UMC PAH-cohort	14
Putting ethics and clinical decision making before politics: requiring COVID-19 immunization for Solid Organ Transplantation (SOT) Candidates and their Support Team	13
Ex-situ oxygenated hypothermic machine perfusion in donation after circulatory death heart transplantation following either direct procurement or in-situ normothermic regional perfusion	13
Chronic lung allograft dysfunction is associated with an early increase of circulating cytotoxic CD4+CD57+ILT2+ T cells, selectively inhibited by the immune check-point HLA-G	13
Circulating microRNAs in cellular and antibody-mediated heart transplant rejection	13
Right ventricular area strain from 3-dimensional echocardiography: Mechanistic insight of right ventricular dysfunction in pediatric pulmonary hypertension	13
HLA-DRB1 mismatch-based identification of donor-derived cell free DNA (dd-cfDNA) as a marker of rejection in heart transplant recipients: A single-institution pilot study	13
Preventing alloimmune rejection using circular RNA FSCN1-silenced dendritic cells in heart transplantation	13
Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension - An analysis of FREEDOM-EV	13
The modified US heart allocation system improves transplant rates and decreases status upgrade utilization for patients with hypertrophic cardiomyopathy	13
Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation	13
International experience using a durable, centrifugal-flow ventricular assist device for biventricular support	13
Lung transplantation disparities based on diagnosis for patients bridging to transplant on extracorporeal membrane oxygenation	13
The Future of heart procurement with donation after circulatory death: Current practice and opportunities for advancement	13
Clinical and hemodynamic characteristics of the pediatric failing Fontan	13
Monitoring of perfusion quality and prediction of donor heart function during ex-vivo machine perfusion by myocardial microcirculation versus surrogate parameters	13
Outcomes of bariatric surgery in patients with left ventricular assist device	13
LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events	13
Safety of reduced anti-thrombotic strategy in patients with HeartMate 3 left ventricular assist device	13
Sex disparities in the current era of pediatric heart transplantation in the United States	13
Early report from the Pediatric Heart Transplant Society on COVID-19 infections in pediatric heart transplant candidates and recipients	13
Higher levels of allograft injury in black patients early after heart transplantation	13
Nothing but NETs: Cytokine adsorption correlates with lower circulating nucleosomes and is associated with decreased primary graft dysfunction	13
Immunologic risk stratification of pediatric heart transplant patients by combining HLAMatchmaker and PIRCHE-II	13
Long-term adult congenital heart disease survival after heart transplantation: A restricted mean survival time analysis	12
Post-transplant diabetes mellitus following heart transplantation	12
Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension	12
Comparison of the safety and efficacy of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension patients with surgically accessible and inaccessible lesions	12
Machine-learning–based exploration to identify remodeling patterns associated with death or heart-transplant in pediatric-dilated cardiomyopathy	12
International society for heart and lung transplantation statement on transplant ethics	12
Ventilation parameters and early graft function in double lung transplantation	12
Whole transcriptome profiling of prospective endomyocardial biopsies reveals prognostic and diagnostic signatures of cardiac allograft rejection	12
COMPETENCE Trial: The EVAHEART 2 continuous flow left ventricular assist device	12
Impact of cytomegalovirus infection on gene expression profile in heart transplant recipients	12
Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction	12
Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation	12
Economic evaluations and costing studies of lung transplantation: A scoping review	12
Vascular pathobiology of pulmonary hypertension	12
Gastrointestinal angiodysplasia in heart failure and during CF LVAD support	12
Bacteriophage therapy as a treatment option for complex cardiovascular implant infection: The German Heart Center Berlin experience	12
Temporal trends in the use and outcomes of temporary mechanical circulatory support as a bridge to cardiac transplantation in Spain. Final report of the ASIS-TC study	12
Unmasking right ventricular-arterial uncoupling during fluid challenge in pulmonary hypertension	12
Machine learning, artificial intelligence and mechanical circulatory support: A primer for clinicians	12
WITHDRAWN: Executive Summary - The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients	12
Abnormal one-year post-lung transplant spirometry is a significant predictor of increased mortality and chronic lung allograft dysfunction	12
Practice variation in the diagnosis of acute rejection among pediatric heart transplant centers: An analysis of the pediatric heart transplant society (PHTS) registry	12
Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension	12
First 5-year multicentric clinical trial experience with the HeartMate 3 left ventricular assist system	12
Hypothermic oxygenated perfusion (HOPE) safely and effectively extends acceptable donor heart preservation times: Results of the Australian and New Zealand trial	12
A national assessment of one-year heart outcomes after the 2018 adult heart allocation change	12
Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction	11
The dynamic cellular landscape of grafts with acute rejection after heart transplantation	11
Recovery of left ventricular function is associated with improved outcomes in LVAD recipients	11
Plasma kallikrein predicts primary graft dysfunction after heart transplant	11
Assessing the accuracy of the lung allocation score	11
Ethics and the emerging use of pig organs for xenotransplantation	11
Fate of the liver in the survivors of adult heart transplant for a failing Fontan circulation	11
Strong evidence for parasympathetic sinoatrial reinnervation after heart transplantation	11
Influence of the microbiome on solid organ transplant survival	11
Full recovery of right ventricular systolic function in children undergoing bilateral lung transplantation for severe PAH	11
Venous thromboembolism in lung transplant recipients real world experience from a high volume center	11
Factors contributing to exercise capacity in chronic thromboembolic pulmonary hypertension with near-normal hemodynamics	11
Interferon-stimulated and metallothionein-expressing macrophages are associated with acute and chronic allograft dysfunction after lung transplantation	11
Comparison of de novo donor-specific antibodies between living and cadaveric lung transplantation	11
Central venoarterial extracorporeal membrane oxygenation as a bridge to recovery after pulmonary endarterectomy in patients with decompensated right heart failure	11
Immune response to COVID-19 in older adults	11
Residual mitral regurgitation in patients with left ventricular assist device support – An INTERMACS analysis	11
Patient factors associated with left ventricular assist device infections: A scoping review	11
Impact of incorporating long-term survival for calculating transplant benefit in the US lung transplant allocation system	11
Cardiac allograft vasculopathy and secondary outcomes of hepatitis C-positive donor hearts at 1 year after transplantation	11
Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients	11
Diagnostic value of serum miR-144-3p for the detection of acute cellular rejection in heart transplant patients	10
Restrictive allograft syndrome vs bronchiolitis obliterans syndrome: Immunological and molecular characterization of circulating exosomes	10
Durable mechanical circulatory support across the Asia-Pacific region	10
Children from socioeconomically disadvantaged communities present in more advanced heart failure at the time of transplant listing	10
Hemodynamic reserve predicts early right heart failure after LVAD implantation	10
Survival implications of prescription opioid and benzodiazepine use in lung transplant recipients: Analysis of linked transplant registry and pharmacy fill records	10
Assessing predicted heart mass size matching in obese heart transplant recipients	10
Characterization of infected, explanted ventricular assist device drivelines: The role of biofilms and microgaps in the driveline tunnel	10
Cocaine use in organ donors and long-term outcome after heart transplantation: An International Society for Heart and Lung Transplantation registry analysis	10
Combined heart–lung transplantation from a donation after circulatory death donor	10
Exercise hyperventilation and pulmonary gas exchange in chronic thromboembolic pulmonary hypertension: Effects of balloon pulmonary angioplasty	10
Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation	10
Determining the impact of ex-vivo lung perfusion on hospital costs for lung transplantation: A retrospective cohort study	10
The lung allocation score and other available models lack predictive accuracy for post-lung transplant survival	10
Detection and management of HLA sensitization in candidates for adult heart transplantation	10
Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies	10
Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant	10
Relationship of ventricular assist device support duration with pediatric heart transplant outcomes	10
Cytomegalovirus replication is associated with enrichment of distinct γδ T cell subsets following lung transplantation: A novel therapeutic approach?	10